Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats

Journal of Periodontal Research

Volumn 46, Issue 6, 2011, Pages 643-647

  Breivik, T ^a,b   Gundersen, Y ^b   Gjermo, P ^a   Taylor, S M ^c   Woodruff, T M ^c   Opstad, P K ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN DEFENCE RESEARCH ESTABLISHMENT FFI   (Norway)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Complement system; Cytokine; Lipopolysaccharide; Periodontitis; Rat

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; CYCLOPEPTIDE; DRINKING WATER; HYDROCINNAMATE (OP(PHE)WR); HYDROCINNAMATE ACF (OP(PHE)WR); HYDROCINNAMATE CYCLO(ORNITHYL PROLYL CYCLOHEXYLALANYL TRYPTOPHYL ARGINYL); HYDROCINNAMATE-(OP(PHE)WR); HYDROCINNAMATE-ACF-(OP(PHE)WR); HYDROCINNAMATE-CYCLO(ORNITHYL-PROLYL-CYCLOHEXYLALANYL-TRYPTOPHYL-ARGINYL); IMMUNOLOGIC FACTOR;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; COMPLEMENT ACTIVATION; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; IMMUNOTHERAPY; LIGATION; METHODOLOGY; PERIODONTITIS; RANDOMIZATION; RAT; WISTAR RAT;

ALVEOLAR BONE LOSS; ANIMALS; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; DRINKING WATER; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LIGATION; PEPTIDES, CYCLIC; PERIODONTITIS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTOR, ANAPHYLATOXIN C5A;

EID: 80054953020     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2011.01383.x     Document Type: Article

References (49)

1. Genco RJ. Current view of risk factors for periodontal diseases. J Periodontol 1996;67:1041-1049.
2. Preshaw PM, Seymour RA, Heasman PA. Current concepts in periodontal pathogenesis. Dent Update 2004;31:570-574.
3. Tatakis DN, Kumar PS. Etiology and pathogenesis of periodontal diseases. Dent Clin North Am 2005;49:491-516.
4. Kornman KS. Mapping the pathogenesis of periodontitis: a new look. J Periodontol 2008;79:1560-1568.
5. Peruzzo DC, Benatti BB, Ambrosano GM et al. A systematic review of stress and psychological factors as possible risk factors for periodontal disease. J Periodontol 2007;78:1491-1504.
6. Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000 2005;38:135-187.
7. Breivik T, Rook GA. Oral treatment with SR299 (killed Mycobacterium vaccae) inhibits experimental periodontal disease in Wistar rats. J Clin Periodontal 2003;30:931-936.
8. Breivik T, Opstad PK, Engstad R, Gundersen G, Gjermo P, Preus H. Soluble β-1, 3/1, 6-glucan from yeast inhibits experimental periodontal disease in Wistar rats. J Clin Periodontal 2005;32:347-352.
9. Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001;38:175-187.
10. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007;449:819-826.
11. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-852.
12. Freudenberg MA, Galanos C. Interaction of lipopolysaccharides and lipid A with complement in rats and its relation to endotoxicity. Infect Immun 1978;19:875-882.
13. Ward PA. Functions of C5a receptors. J Mol Med 2009;87:375-378.
14. Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, Taylor SM. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res 2002;103:260-267.
15. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol 2004;142:756-764.
16. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 2003;171:5514-5520.
17. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res 2004;116:81-90.
18. Woodruff TM, Proctor LP, Taylor SM. Complement factor C5a as a therapeutic target. Drugs Future 2006;31:325-334.
19. Woodruff TM, Pollitt S, Proctor LM et al. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther 2005;314:811-817.
20. Liang S, Krauss JL, Domon H et al. The C5a Receptor Impairs IL-12-Dependent Clearance of Porphyromonas gingivalis and Is Required for Induction of Periodontal Bone Loss. J Immunol 2010;186:869-877.
21. Wang M, Krauss JL, Domon H et al. Microbial hijacking of complement-toll-like receptor crosstalk. Sci Signal 2010;3:ra11.
22. Gustafsson A, Ito H, Asman B, Bergström K. Hyper-reactive mononuclear cells and neutrophils in chronic periodontitis. J Clin Periodontol 2006;33:126-129.
23. Guentsch A, Puklo M, Preshaw PM et al. Neutrophils in chronic and aggressive periodontitis in interaction with Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. J Periodontal Res 2009;44:368-377.
24. Allegretti M, Moriconi A, Beccari AR et al. Targeting C5a: recent advances in drug discovery. Curr Med Chem 2005;12:217-236.
25. Marder SR, Chenoweth DE, Goldstein IM, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol 1985;134:3325-3331.
26. Czermak BJ, Breckwoldt M, Ravage ZB et al. Mechanisms of enhanced lung injury during sepsis. Am J Pathol 1999;154:1057-1065.
27. Fittschen C, Sandhaus RA, Worthen GS, Henson PM. Bacterial lipopolysaccharide enhances chemoattractant-induced elastase secretion by human neutrophils. J Leukoc Biol 1988;43:547-556.
28. March DR, Proctor LM, Stoermer MJ et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activit. Mol Pharmacol 2004;65:868-879.
29. Soruri A, Riggert J, Schlott T, Kiafard Z, Dettmer C, Zwirner J. Anaphylatoxin C5a induces monocyte recruitment and differentiation into dendritic cells by TNF-alpha and prostaglandin E2-dependent mechanisms. J Immunol 2003;171:2631-2636.
30. Morgan EL. Modulation of the immune response by anaphylatoxins. Complement 1986;3:128-136.
31. Bhandari V, Elias JA. Cytokines in tolerance to hyperoxia-induced injury in the developing and adult lung. Free Radic Biol Med 2006;41:4-18.
32. Lorenzetti BB, Veiga FH, Canetti CA, Poole S, Cunha FQ, Ferreira SH. Cytokine-induced neutrophil chemoattractant 1 (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats. Eur Cytokine Netw 2002;13:456-461.
33. Collins PD, Jose PJ, Williams TJ. The sequential generation of neutrophil chemoattractant proteins in acute inflammation in the rabbit in vivo. Relationship between C5a and proteins with the characteristics of IL-8/neutrophil-activating protein 1. J Immunol 1991;146:677-684.
34. Watanabe K, Koizumi F, Kurashige Y, Tsurufuji S, Nakagawa H. Rat CINC, a member of the interleukin-8 family, is a neutrophil-specific chemoattractant in vivo. Exp Mol Pathol 1991;55:30-37.
35. Ting E, Guerrero AT, Cunha TM et al. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol 2008;153:1043-1053.
36. Breivik T, Gundersen Y, Gjermo P, von Hörsten S, Fristad I, Opstad PK. Systemic chemical desensitization of peptidergic sensory neurons with resiniferatoxin inhibits experimental periodontitis. Open Dent J 2011;5:1-6.
37. Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 1995;345:99-103.
38. Eskandari F, Sternberg EM. Neural immune interaction in health and disease. Ann N Y Acad Sci 2002;966:20-27.
39. Elenkov IJ. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int 2008;52:40-51.
40. Breivik T, Opstad PK, Gjermo P, Thrane PS. Effects of hypothalamic-pituitary-adrenal axis reactivity on periodontal tissue destruction in rats. Eur J Oral Sci 2000;108:115-122.
41. Breivik T, Thrane PS, Gjermo P, Opstad PK. Glucocorticoid receptor antagonist RU-486 treatment reduces periodontitis in Fischer 344 rats. J Periodont Res 2000;35:285-290.
42. Breivik T, Thrane PS, Gjermo P, Opstad PK, Pabst R, von Horsten S. Hypothalamic-pituitary-adrenal axis activation by experimental periodontal disease in rats. J Periodont Res 2001;36:295-300.
43. Breivik T, Gundersen Y, Opstad PK, Fonnum F. Chemical sympathectomy inhibits periodontal disease in Fischer 344 rats. J Periodont Res 2005;40:325-330.
44. Breivik T, Gundersen Y, Osmundsen H, Opstad PK, Fonnum F. Chronic treatment with the glutamate receptor antagonist MK-801 alters periodontal disease susceptibility. J Periodont Res 2005;40:28-35.
45. Breivik T, Gundersen Y, Myhrer T et al. Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the antidepressant tianeptine. J Clin Periodontol 2006;33:469-477.
46. Breivik T, Gundersen Y, Gjermo P, Von Hörsten S, Opstad PK. Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis. J Periodont Res 2009;44:297-303.
47. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003;82:82-90.
48. Krauss JL, Potempa J, Lambris JD, Hajishengallis G. Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host. Periodontol 2000 2010;52:141-162.
49. Hajishengallis G. Complement and periodontitis. Biochem Pharmacol 2010;15:1999-2001.